Category: Drug Checking Report
Posted: June 23 2020
Author: CDPE

Results from Samples Checked by Toronto’s Drug Checking Service: June 6 – 19, 2020

Checked Samples by Sample Type

Between June 6 – 19, 2020, 22 samples were checked: 68% (15) were substances and 32% (7) were post-use paraphernalia.

 

Checked Samples by Expected Drug

When a client submits a sample to be checked, they indicate which drug they expect that sample to contain. Of the 22 samples checked between June 6 – 19, 2020:

  • 12 were expected to be fentanyl
  • 2 were expected to be cocaine
  • 4 were expected to be other drugs, including: amphetamine, LSD, MDMA, and methamphetamine
  • 4 did not have a stated expected drug

 

Expected Fentanyl Samples

Of the 22 samples checked between June 6 – 19, 2020, 55% (12) were expected to be fentanyl (67% were substances and 33% were post-use paraphernalia).

 

Presence of fentanyl in expected fentanyl samples (12)

  • 100% (12) contained fentanyl and other drugs

 

Expected fentanyl samples containing fentanyl and other drugs (12)

Of the 12 samples expected to be fentanyl, 100% (12) contained fentanyl and other drugs. Other drugs found included:

  • 100% (12) contained caffeine
  • 58% (7) contained one or more benzodiazepine or benzodiazepine-related drug*:
    • 33% (4) of expected fentanyl samples contained flualprazolam*
    • 25% (3) of expected fentanyl samples contained etizolam*
  • 17% (2) contained despropionyl fentanyl (4-ANPP)*
  • 17% (2) contained n-methyl norfentanyl*
  • 8% (1) contained ACHMINACA (synthetic cannabinoid-related)*

 

Other Expected Drug Samples Containing Unexpected Noteworthy Drugs

Of the remaining 10 samples checked between June 6 – 19, 2020, meaning samples that were not expected to be fentanyl, 30% (3) contained one or more unexpected noteworthy drug. Unexpected noteworthy drugs found included:

  • 75% (3) of samples that did not have a stated expected drug contained fentanyl*
  • 25% (1) of samples that did not have a stated expected drug contained one or more benzodiazepine or benzodiazepine-related drug*
  • 25% (1) of samples that did not have a stated expected drug contained despropionyl fentanyl (4-ANPP)*

 

*Unexpected noteworthy drug: “Noteworthy drugs” are drugs that are highly potent, linked to overdose or other adverse effects, or may not be desired by some clients. Noteworthy drugs are called out when they are unexpectedly found in checked samples.